Boston, MA. International law firm Nixon Peabody LLP is proud to have represented Halma plc in its €85 million (approx. $92.6 million) acquisition of cancer screening medical device manufacturer Rovers Medical Devices (Rovers).
Halma, based in Amersham, England, is a publicly traded global group of life-saving technology companies delivering solutions to many of the key problems facing the world today, from improving air and water quality to better healthcare for patients and keeping people safe as our cities grow. This acquisition enables Halma to broaden the range of markets it serves in women’s health and further strengthen its healthcare sector’s position in cancer diagnosis products.
Rovers, based in Oss, Netherlands, designs, develops, manufactures, and markets cell sampling devices for cytological, bacteriological, viral (HPV), and DNA testing materials. The company’s products are used in more than 90 countries all over the world.
“We congratulate the Halma and Rovers teams on the completion of this deal,” said Daniel Belostock, a partner with Nixon Peabody’s Corporate practice, who led the deal team. “This transaction enables both companies to focus on their missions of improving the quality of care for patients worldwide.”
Rovers will remain a standalone company within Halma’s healthcare sector, led by its current management team.
In addition to Belostock, the Nixon Peabody team included partners Seth Levy, Alexandra Lopez-Casero, Hannah Bornstein, and Kevin Grant; associates Ben Rosborough and Tim Sharkey; paralegal Timothy Fiester; and legal intern Jule Giegling. Law firm Taylor Wessing served as European counsel.
